Newest Treatment for Schizophrenia & Related Psychotic Disorders Now
Available to All Quebecers
From the PharmaLive.com News Archive - Oct. 26, 2010
Bristol-Myers Squibb Canada is pleased to announce that Quebec has
recognized the value of Abilify (aripiprazole) for the treatment of
schizophrenia and related psychotic disorders in adults and has
agreed to list Abilify as a reimbursed full benefit on the Quebec
public drug plans as of October 14, 2010.
"People Who experience mood swings, fear, voices and visions"